SES
2.4.2020 15:16:08 CEST | Business Wire | Press release
SES S.A. held its Annual General Meeting (AGM) today in Betzdorf, Luxembourg, in which all resolutions were approved by shareholders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200402005503/en/
The meeting was held based on the rules set out in the Grand Ducal Regulation of 20 March 2020 with shareholders participating remotely by appointing SES designated proxyholders to represent them at the meeting and to carry out their voting instructions given ahead of the meeting. Compliance with voting instructions was verified by the bureau of the AGM.
The approved resolutions included the company's 2019 financial accounts and the proposed dividend of EUR 0.40 per A-share which will be paid to shareholders on 23 April 2020. Accordingly, SES’s 2019 Annual Report has been published and is available to download at http://www.ses.com/annual-report .
Shareholders also approved a reduction in Board size from 14 to 12 Directors.
In addition, shareholders elected Béatrice de Clermont-Tonnerre and Peter van Bommel for an initial two-year mandate and elected Paul Konsbruck and Frank Esser for another three-year mandate. They also re-elected Ramu Potarazu, Kaj-Erik Relander and Anne-Catherine Ries for three years.
In the context of the reduction in Board size, shareholders also noted the resignations of Victor Casier, Hadelin de Liedekerke Beaufort, Marc Serres and François Tesch as Directors of SES. The AGM thanked those Directors for their contributions.
Consequently, the Board is now composed as follows: A-shareholders are represented by (all of them independent) Romain Bausch, Béatrice de Clermont-Tonnerre, Frank Esser, Tsega Gebreyes, Ramu Potarazu, Kaj-Erik Relander, Peter van Bommel, Katrin Wehr-Seiter; and B-shareholders are represented by Serge Allegrezza, Paul Konsbruck, Anne-Catherine Ries, Françoise Thoma.
At the AGM, Romain Bausch, Chairman of the SES Board and former President and CEO, informed the shareholders that he would not seek a new mandate as Chairman. Mr Bausch will remain on the Board as an independent Director.
Accordingly, in its meeting following the AGM, the Board of Directors elected Frank Esser as Chairperson of the Board for a period of one year and re-elected both Tsega Gebreyes and Anne-Catherine Ries as Vice-Chairpersons of the Board, also for a period of one year.
“Having been at the helm of the company for 25 years, firstly as CEO and latterly as Chairman and with the company now entering an exciting period of transformation under Steve Collar’s leadership and with a newly invigorated and streamlined Board, I consider it to be the right time to pass the baton to a new Chair in the renewed Board,” said Romain Bausch. “It has been a true privilege to serve SES in these different roles and I want to thank our shareholders for their continued support.”
“I am honoured to be elected Chairperson at this important and exciting time for our company with SES being in a great position for further development,” said Frank Esser. “I am delighted to be joining the Board with several new Directors who will each bring strong competencies, complementing those of the rest of our Board colleagues. I would also like to take this opportunity to pay tribute to Romain and his contribution, commitment and on-going service to SES with his continued presence as a Director.”
Follow us on:
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of over 365 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005503/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom